Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,370.00
+85.00 (2.59%)
At close: Sep 9, 2026

Genome & Company Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
49,91215,59865,54956,35672,21636,049
Short-Term Investments
3,22012,5108,22718,86328,20535,249
Trading Asset Securities
11,1698,7227,15511,0536,2785,865
Cash & Short-Term Investments
64,30136,83080,93086,272106,69977,164
Cash Growth
8.46%-54.49%-6.19%-19.14%38.28%-29.59%
Accounts Receivable
2,2771,8552,0601,4021,957759.22
Other Receivables
583.14,383382.721,544864.23992.14
Receivables
2,8606,2382,4422,9462,8211,751
Inventory
9,7045,9795,7713,5682,2381,327
Prepaid Expenses
1,1081,113690.721,1501,1591,102
Other Current Assets
1,1152,1342,0943,1143,994433.15
Total Current Assets
79,08852,29491,92897,050116,90981,777
Property, Plant & Equipment
19,86920,56827,87034,62421,52616,475
Long-Term Investments
3,941-0----
Goodwill
11,05711,05714,13314,13316,45816,458
Other Intangible Assets
4,5375,6568,25611,10213,92118,388
Other Long-Term Assets
4,48855,4335,1485,1524,1824,119
Total Assets
122,981145,008147,335162,060172,997137,216

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
641.14509.05481.2340.19205.18321.4
Accrued Expenses
1,0101,3731,7292,7233,4281,713
Short-Term Debt
12,4216,32518,40112,634--
Current Portion of Long-Term Debt
9,0009,000----
Current Portion of Leases
1,4161,3161,2281,0552,0241,583
Current Income Taxes Payable
-0.15----
Other Current Liabilities
9,7014,1157,97312,1315,4846,208
Total Current Liabilities
34,18922,63829,81228,88311,1419,826
Long-Term Debt
--9,0009,000--
Long-Term Leases
1,9742,3263,3953,7644,2675,243
Long-Term Deferred Tax Liabilities
1,9402,1803,2424,4145,5826,826
Other Long-Term Liabilities
3,5833,2872,8202,4821,4621,921
Total Liabilities
41,68630,43248,27048,54322,45223,816

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
22,58917,32415,5277,3637,0467,033
Additional Paid-In Capital
361,505306,966296,475304,765304,724257,345
Retained Earnings
-359,675-311,199-304,771-284,659-237,193-185,355
Comprehensive Income & Other
42,66387,99240,19834,24021,78413,710
Total Common Equity
67,082101,08347,42861,70896,36092,733
Minority Interest
9,3418,80150,75351,08953,24820,667
Shareholders' Equity
81,295114,57799,065113,517150,544113,400
Total Liabilities & Equity
122,981145,008147,335162,060172,997137,216

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
24,81118,96732,02426,4536,2916,826
Net Cash (Debt)
39,49017,86248,90659,819100,40870,338
Net Cash Growth
23.96%-63.48%-18.24%-40.42%42.75%-34.77%
Net Cash Per Share
1126.06570.491604.882118.263566.882616.46
Filing Date Shares Outstanding
42.2234.6531.0529.4528.1828.13
Total Common Shares Outstanding
42.2234.6531.0529.4528.1828.13
Working Capital
44,90029,65662,11568,167105,76971,952
Book Value Per Share
1588.922917.361527.272095.343419.083296.30
Tangible Book Value
51,48784,37025,04036,47365,98157,888
Tangible Book Value Per Share
1219.542435.01806.311238.472341.162057.68
Land
1,8191,8192,6992,71010.59-
Buildings
6,2126,2129,2519,220--
Machinery
21,15717,59118,06315,83814,6629,167
Construction In Progress
-2,6922,5038,4924,2452,262